Francis P. Worden, MD, on Vismodegib: Organ Preservation for Orbital/Periocular Basal Cell Carcinoma

Posted: Monday, July 13, 2020

Francis P. Worden, MD, of the University of Michigan Health System Comprehensive Cancer Center, discusses vismodegib as a potentially practice-changing neoadjuvant treatment for patients with locally advanced periocular basal cell carcinoma of the eye and lacrimal drainage system, in which surgery would result in unacceptable morbidity.